Strategic partnership Leverage the collaboration with Dana-Farber Cancer Institute to position as a validated ex vivo platform for oncology drug testing, offering co-branded studies and joint publications to accelerate customer credibility and engagement.

Clinical predictive edge Highlight human tissue-based modeling and tumor microenvironment capture as a differentiator from traditional in vivo models, targeting biotech and pharma teams seeking higher translational predictability and reduced clinical risk.

Data integration advantage Emphasize the cloud platform that unifies tissue, patient, and results data with AI-driven analytics to accelerate hypothesis testing and mechanistic understanding, appealing to decision makers seeking faster go/no-go decisions.

Expansion opportunities Target mid-sized biotech firms and oncology-focused startups looking to de-risk early-stage programs by incorporating ex vivo assessments, offering scalable engagement from pilot studies to broader modality coverage.

Financial readiness Position as a cost- and time-saving complement to in vivo work by reducing late-stage failures, aligning with potential partners’ funding cycles and risk-mitigation strategies given the current revenue and funding profile.